Although aberrant activation of STAT3 or STAT5 has been reported in a variety of human cancers, determining the activation state of STAT3 or STAT5 may permit evaluating the clinical potential of JAK2 inhibitors [28]. This evidence concerns the gene JAK2 and cancer.